Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. - Wikidata - awgldk - TriplyDB

Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.

Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.

http://www.wikidata.org/entity/Q40953949

about

Evolution of animal models in cancer vaccine development Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial Anti-HER2 vaccines: new prospects for breast cancer therapy Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.Synthetic peptides as cancer vaccines.Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.Inhibition of tumor progression during allergic airway inflammation in a murine model: significant role of TGF-β.Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression.Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice.The "A, B and C" of Her-2 DNA vaccine development.A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.

P2860

Q28080739-6DE55A3A-5057-4903-8F71-717A8F655F8C Q28596492-5C04A1F5-2D4A-4855-8C12-F7B7EE7EFF3E Q33699124-1F5835DC-5ED9-4CDC-B9B2-62BF404AEF67 Q33991804-82E39773-82CF-4DFE-88BE-B912A9A92898 Q34105959-B58DBA78-1661-4242-AA89-1FB2C8B1B6C7 Q34288183-5CC9DB10-98CD-4F5E-9D0B-919476B9AD68 Q34427467-001883D7-388A-4C84-8A98-40D963A898FD Q34505825-128567AD-1EBA-4F88-A0C1-110AABC0DB3D Q34505881-E0110ADA-1100-4F7E-A39D-5C27F18A6043 Q34972916-47087D30-5089-4C1D-9395-A425D23DDCC1 Q35056217-49FF8E89-0CC8-458E-9F45-470838C86A59 Q35201826-5BCF75DC-5C65-4F6C-A184-13D99D3AC1E7 Q35815995-D77F8FB9-B94C-4A55-B696-D9C874EBB18A Q35840314-EBB7D1AC-3DD0-42EC-A9A9-15E48246E356 Q35967977-1684EB53-6DE4-43A9-B893-D773EBD0F6C3 Q36070101-AD8948A0-CAE2-47B5-9EA5-61C8F429FAF8 Q36207818-ED293BC9-EF97-4C7C-9217-789A9D3E08F2 Q36245418-A21D2981-8B5C-4945-AC3A-4D0542997D06 Q36924836-032417EA-AA0A-4CCC-8115-F886C8E22F79 Q36984725-38846AEB-CC2F-4EAE-AEE1-AF3FF79B71AF Q37035553-2501203A-84F2-4027-9AA0-8664F9E249EC Q37036281-35A308E8-E64B-4601-AF53-357333668034 Q37084243-90CB782C-225A-409F-9043-C59B93B998D6 Q37162704-6806BB91-6E6B-49A6-A1D2-CF8EB43552DF Q37307584-9024B7C6-4256-4C7A-AC4C-06D19EACE465 Q37309250-6B0B551F-1ACC-47C2-B528-59576F70AB37 Q37355020-6F0110DA-3A59-4254-AA3F-7851067C300C Q37626805-38881AC9-12ED-42B0-B051-80D9CC93B5CC Q37678070-392C7DE0-E0B5-4CB7-986B-D21D2A2929F0 Q40811138-06EC16BF-29FF-4DF9-9287-8C5AD48CEA3C Q41936513-43E6C092-588F-45B1-B16A-1DD23923D9AE Q45858638-7ADA2863-DACF-40C3-B4D0-A64E81505944 Q45877906-296B561A-CBE6-43C2-AD62-6AFEF2C144F5 Q52890329-7522581E-D403-40E7-B0AB-E7CC4AA0247F Q54252199-C4EFC3E6-3FEA-420F-B6E8-708652B4ECF5

P2860

Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.

http://www.wikidata.org/entity/Q40953949

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Protection against mammary tum ...... th, modified human ErbB-2 DNA.

@en

type

label

Protection against mammary tum ...... th, modified human ErbB-2 DNA.

@en

prefLabel

Protection against mammary tum ...... th, modified human ErbB-2 DNA.

@en

P1433

Q40953949-07A69478-A449-4E05-A6AA-F1B9E78E668E

P1476

Q40953949-24E858D8-B200-4472-805B-8F3D0A77F4B4

P2093

Q40953949-38940220-E223-4340-BE9A-513A4CBFA296

Q40953949-3AE66083-C712-47D9-8F28-A419EFB2C0CD

Q40953949-5037A35A-F422-49C8-B1B9-C144BEB02131

Q40953949-79D8423E-E85A-437E-8204-15A739427D4C

Q40953949-7BE4DC88-5B70-47DC-BB45-3DE10D42D479

Q40953949-D429E73B-DEAA-444D-B5DB-7FA1E45802EA

Q40953949-E44DC6A7-61D1-4C5B-BE6D-6ACF832FBFCC

Q40953949-E4E21456-7F44-4D3B-8A71-A698113AD189

P2860

Q40953949-03BC16D1-8DED-4429-A506-3B591CC5CB2F

Q40953949-14E043E5-26D2-464E-BC7E-BD5C0590CE1E

Q40953949-17FD9C32-19FC-4C91-AE1F-9F5FC46F424E

Q40953949-38BF01EE-2740-4CB1-BB86-2CFD5ADF9BFD

Q40953949-42E19658-1CB5-493B-B7D3-97B296C104B9

Q40953949-68588CC6-58DE-46C1-95BF-FCAE0D619362

Q40953949-7A68154C-CFD3-4712-BBCB-B403EA81B221

Q40953949-7B4115C4-49ED-49B2-A273-A895ED868643

Q40953949-83EB8C4C-015B-4BB7-9570-09D9D988F6E9

Q40953949-945E5AE5-4730-416E-A943-B2A1379BF724

P304

Q40953949-03F79994-2559-4F46-BAB1-4042743E2027

P31

Q40953949-FFFF4F16-5998-4675-BF35-376CCA168C85

P356

Q40953949-9C9A740F-59F9-405B-8A74-66B262603E79

P433

Q40953949-7BC56F65-EE1A-4680-BE84-DB7230189E91

P478

Q40953949-840EDA72-2DFB-4E3C-B119-4E4A5B110D0E

P577

Q40953949-2FAB920B-947F-46EA-A425-A1390730B037

P698

Q40953949-F1111D93-4F83-4EC2-9198-2EB8204CB7E8

P356

(SICI)1097-0215(19990531)81:5%3C748::AID-IJC14%3E3.0.CO;2-6

P1433

International Journal of Cancer

P1476

Protection against mammary tum ...... th, modified human ErbB-2 DNA.

@en

P2093

A Galy

http://www.w3.org/2001/XMLSchema#string

B Groner

http://www.w3.org/2001/XMLSchema#string

D Lichlyter

http://www.w3.org/2001/XMLSchema#string

L Heilbrun

http://www.w3.org/2001/XMLSchema#string

R F Jones

http://www.w3.org/2001/XMLSchema#string

S Hernandez

http://www.w3.org/2001/XMLSchema#string

W P Shi

http://www.w3.org/2001/XMLSchema#string

W Z Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Gene vaccination with naked plasmid DNA: mechanism of CTL priming

Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function

T-cell antigen receptor genes and T-cell recognition

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

A molecular model of MHC class-I-restricted antigen processing.

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.

Intracellular transport of MHC class II molecules.

P304

748-754

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

1999-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10328228

http://www.w3.org/2001/XMLSchema#string